论文部分内容阅读
目的探讨肝动脉化疗栓塞联合全身静脉推注三氧化二砷(AS2O3)治疗原发性肝癌的近期疗效。方法对32例中晚期原发性肝癌病人采用常规药物经皮肝动脉化疗栓塞治疗,间隔4周1周期,2~3个周期后观察疗效。同时给予三氧化二砷注射液10~15mg静脉滴注,1次/d,连用14d,间隔2周重复。结果近期疗效,均按要求完成2~3个周期,随访1年以上,PR13例,NC14例,PD5例,总有效率40.6%,临床获益率为84.4%。生活质量,改善18例(56.3%),稳定11例(34.4%)。不良反应少。结论肝动脉化疗栓塞(TACE)联合静脉推注三氧化二砷治疗中晚期原发性肝癌近期疗效较好,毒不良反应少。
Objective To investigate the short-term curative effect of transcatheter arterial chemoembolization combined with intravenous arsenic trioxide (AS2O3) in the treatment of primary liver cancer. Methods Thirty-two patients with primary hepatocellular carcinoma (HCC) underwent percutaneous transhepatic arterial chemoembolization. The patients were divided into 4 cycles of 1 cycle and 2 to 3 cycles of treatment. At the same time give arsenic trioxide injection 10 ~ 15mg intravenous infusion, 1 / d, once every 14d, repeated 2 weeks intervals. Results The short-term curative effect was completed within 2 to 3 cycles according to the requirements. The patients were followed up for more than 1 year. PR 13, NC 14 and PD 5 had a total effective rate of 40.6% and a clinical benefit rate of 84.4%. Quality of life improved in 18 cases (56.3%) and stable in 11 cases (34.4%). Adverse reactions. Conclusion TACE and intravenous injection of arsenic trioxide in the treatment of advanced primary liver cancer in the near future have better curative effect and less adverse reactions.